B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on relapsed leukemia in early trial
Disease control Recruiting nowThis study tests a new treatment called UCART22 for adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not responded to standard therapies. UCART22 uses donor immune cells that are specially designed to find and attack cancer cells carrying the CD22 marker.…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Jun 16, 2026 22:35 UTC
-
New cell therapy SYNCAR-100 targets stubborn leukemia in early trial
Disease control Recruiting nowThis early study tests a new treatment called SYNCAR-100 for adults with a type of leukemia (B-ALL) that has come back or not responded to standard therapy. The treatment is given once a week for four weeks. The main goals are to check safety and see if it helps control the disea…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New hope for tough blood cancers: drug combo trial opens
Disease control Recruiting nowThis study is for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to treatment. Researchers are adding a new drug, capivasertib, to a standard chemotherapy and venetoclax regimen to see if it is safe and works better. T…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Second-Chance CAR-T therapy tested for blood cancer patients
Disease control Recruiting nowThis study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose CAR-T cell therapy didn't meet commercial quality standards. Researchers want to see if this slightly different product is still safe and effective. About 200 participants wil…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New drug YK012 shows promise in early trial for blood cancer
Disease control Recruiting nowThis study tests a new drug, YK012, in 46 people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The goal is to check if the drug is safe and to see how well it works against the cancer. Participants will receive YK012 alone, and researchers will monitor…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New CAR t-cell combo shows promise against tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) follow…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New Dual-Target CAR t therapy offers hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatments. The main goal is to find a safe dose and see if the t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New 'Sandwich' strategy may boost leukemia survival without donor transplant
Disease control Recruiting nowThis early-phase study tests a new treatment approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The strategy uses the drug blinatumomab before and after a transplant using the patient's own stem cell…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Off-the-shelf cell therapy takes on aggressive blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called Azer-cel, a type of immune cell therapy made from donor cells, for adults with certain blood cancers that have come back or not responded to standard treatments. The goal is to see if it is safe and can shrink tumors or put the …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug cocktail IoVeX offers hope for relapsed leukemia patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 participants will receive the drugs over one or two 2…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New CAR-T therapy offers hope for kids with hard-to-treat leukemia and lymphoma
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy made locally for children whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to target and kill cancer ce…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Double CAR t attack shows promise for tough childhood leukemia
Disease control Recruiting nowThis study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. Participants receive two different types of their own modified immune cells (CAR T cells) designed to target two protei…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study tests a special immune cell treatment (CAR-T cells that target two markers, CD22 and CD19) in 30 people with high-risk B-cell acute lymphoblastic leukemia who are already in their first remission. The goal is to see if this therapy can safely lower the chance of the ca…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Double-Targeted immune cells aim to keep leukemia in remission
Disease control Recruiting nowThis study tests a new treatment for people with a certain type of blood cancer (B-cell acute lymphoblastic leukemia) that is in remission. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack two markers on cancer cells (CD22 and…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New gene therapy aims to outsmart Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New cocktail aims to crush resistant leukemia
Disease control Recruiting nowThis early-phase study tests a new drug (ABL001) combined with two standard drugs and a steroid for people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis. The goal is to find the safest dose and see how well the combination c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
Double CAR t attack: new hope for tough leukemia?
Disease control Recruiting nowThis early-phase study tests a two-step treatment for people with a hard-to-treat type of leukemia (B-cell ALL) that has come back or not responded to standard therapies. First, patients receive donor immune cells engineered to target cancer (CD19 CAR T cells), followed by a stem…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
New hope for kids with tough cancers: experimental drug trial opens
Disease control Recruiting nowThis study tests an experimental drug called zilovertamab vedotin in children and young adults (ages 1 to <18) whose blood cancers (like B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, or Burkitt lymphoma) or solid tumors (neuroblastoma or Ewing sarcoma) have …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC
-
New Dual-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 02, 2026 11:40 UTC
-
New hope for kids with tough leukemia: donor immune cells tested
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults with B-cell leukemia that has come back or not responded to standard therapy. Doctors take immune cells from a healthy donor and modify them to attack cancer cells, then give them to the patient. The main …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC
-
Real-World study tracks Blinatumomab's impact on leukemia patients
Knowledge-focused Recruiting nowThis study gathers information from 200 adults with B-cell acute lymphoblastic leukemia who received blinatumomab as part of their regular care, not in a clinical trial. Researchers will look at how many patients achieve complete remission and how long they live. The goal is to u…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:53 UTC
-
Leukemia treatment may weaken vaccine protection – study seeks answers
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) who received blinatumomab for B-cell acute lymphoblastic leukemia still have protection from their routine childhood vaccines. Researchers will test antibody levels for diseases like tetanus, hepatitis B, and me…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC